Novel AKT pathway inhibitor, ARQ 092, demonstrated safety, effective target inhibition
Researchers have confirmed that the novel oral agent ARQ 092 inhibits the AKT pathway and has a manageable safety profile in patients with a variety of advanced solid tumors, according to phase I data presented at the AACR ...
Apr 9, 2013
0
0